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Sirolimus-Eluting Stents for Treatment
of Coronary Restenosis in Sirolimus-Eluting Stents
The ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results:
Drug Eluting Stents for In-Stent Restenosis 2) Study
Julinda Mehilli, MD,* Robert A. Byrne, MB,* Klaus Tiroch, MD,* Susanne Pinieck,*
Stefanie Schulz, MD,* Sebastian Kufner, MD,* Steffen Massberg, MD,* Karl-Ludwig Laugwitz, MD,†
Albert Schömig, MD,† Adnan Kastrati, MD,* for the ISAR-DESIRE 2 Investigators
Munich, Germany
Objectives For patients with sirolimus-eluting stent (SES) restenosis requiring reintervention, we compared a strategy of
repeat SES (Cypher, Cordis, Miami Lakes, Florida) implantation with paclitaxel-eluting stent (PES) (Taxus, Boston
Scientific, Natick, Massachusetts) implantation.
Background Despite their high anti-restenotic efficacy, the widespread utilization of SES therapy has led to a significant abso-
lute number of patients presenting with SES treatment failure. The optimal treatment strategy for such patients
remains unclear.
Methods The ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2)
study was a randomized, open-label, active-controlled trial conducted among 450 patients with clinically signifi-
cant in-SES restenosis at 2 centers in Munich, Germany. After pre-treatment with 600 mg clopidogrel, all pa-
tients were randomly assigned to either SES or PES implantation. The primary end point was late lumen loss,
based on in-stent analysis, at 6- to 8-month follow-up angiography. Secondary end points were binary angio-
graphic restenosis (diameter stenosis 50%) at 6- to 8-month follow-up, target lesion revascularization, the
composite of death or myocardial infarction, and definite stent thrombosis at 12 months.
Results Regarding anti-restenotic efficacy, there were no differences between SES and PES in late loss (0.40  0.65
mm vs. 0.38  0.59 mm; p  0.85), binary restenosis (19.6% vs. 20.6%; p  0.69), or target lesion revascular-
ization (16.6% vs. 14.6%; p  0.52). In terms of safety outcomes, the rates of death/myocardial infarction
(6.1% vs. 5.8%; p  0.86) and stent thrombosis (0.4% vs. 0.4%; p  0.99) were also similar.
Conclusions In cases of SES restenosis, treatment with either repeat SES or switch to PES was associated with a comparable
degree of efficacy and safety. Drug resistance at an individual patient level may play a contributory role to the
somewhat higher than expected late loss observed with the SES in the current study. (Intracoronary Stenting and
Angiographic Results: Drug-Eluting Stents for In-Stent Restenosis 2 [ISAR-DESIRE 2]; NCT00598715) (J Am
Coll Cardiol 2010;55:2710–6) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.02.009m
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wrug-eluting stent (DES) therapy has undoubtedly repre-
ented a significant success in the battle against coronary artery
estenosis (1). The widespread adoption of this technology into
outine clinical practice, however, has led to significant absolute
umbers of patients presenting with DES treatment failure. In
he U.S. alone, it is estimated that as many as 200,000 cases of
ES restenosis may occur every year (2).
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r. Kastrati has received lecture fees from Cordis and Medtronic. An abstract of this work 2For patients with DES restenosis, the optimal manage-
ent strategy remains unknown. The predominantly focal
See page 2717
attern of restenosis (3–5) and the lessons learned from the
anagement of bare metal stent restenosis—where DES
as presented as a Late Breaking Clinical Trial at Transcatheter Cardiovascular
herapeutics 2009 in San Francisco, California. The study design, analysis, and funding
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June 15, 2010:2710–6 Treatment of SES Restenosisherapy proved superior to balloon angioplasty and vascular
rachytherapy (6–9)—makes treatment with repeat DES an
ttractive option. However, it remains to be determined
hether implantation of DES eluting the same type of
rug—a so-called “homo-DES” approach—is preferable to a
witch to a DES eluting a different class of drug—a “hetero-
ES” strategy.
The specific setting of sirolimus-eluting stent (SES) resteno-
is is a case in point, and its management a matter of clinical
quipoise. On the one hand, it is conceivable that patients
ith SES treatment failure may possess specific factors
such as hyporesponsiveness to sirolimus) that would favor a
witch to treatment with a paclitaxel-eluting stent (PES).
n the other hand, the superior neointimal suppression
een with first-generation SES as compared with PES may
e particularly apposite in the setting of a high risk of
ecurrent restenosis. To investigate this issue, we randomly
ssigned patients with SES restenosis to repeat SES im-
lantation (Cypher, Cordis, Miami Lakes, Florida) or to
witch to PES therapy (Taxus, Boston Scientific, Natick,
assachusetts).
ethods
tudy population, randomization, and intervention protocol.
etween October 2007 and January 2009, patients 18
ears of age with ischemic symptoms or evidence of myo-
ardial ischemia (inducible or spontaneous) in the presence
f a restenosis 50% located in the native vessel segment
reated with SES were considered eligible, provided that
ritten, informed consent by the patient or a legally
uthorized representative for participation in the study was
btained. Patients with restenosis occurring in either the
irolimus-eluting Cypher stent (Cordis) or the sirolimus-
luting ISAR (individualizable stent to abrogate restenosis)
tent (based on Yukon [Translumina, Hechingen, Ger-
any] backbone) (10) were considered eligible for partici-
ation in the study. Patients with a target lesion located in
he left main stem, acute myocardial infarction within the
receding 48 h, cardiogenic shock, malignancies, or other
omorbid conditions with life expectancy 12 months or
hat may result in protocol noncompliance, known allergy to
he study medications (sirolimus, paclitaxel), or pregnancy
present, suspected, or planned) were considered ineligible
or the study. The study was conducted in accordance with
he provisions of the Declaration of Helsinki and with the
nternational Conference on Harmonization Good Clinical
ractices. The trial protocol was approved by the institu-
ional ethics committee responsible for the participating
enters, Deutsches Herzzentrum and 1. Medizinische Klinik,
linikum Rechts der Isar, both in Munich, Germany.
In each participating center, allocation to treatment was
ade by means of sealed, opaque envelopes containing a
omputer-generated sequence; randomization was performed
mmediately after the decision to proceed with percutaneous
oronary intervention (PCI). Patients who met all of the Mnclusion criteria and none of the
xclusion criteria were randomized
n the order that they qualified.
andomization was stratified ac-
ording to participating center.
atient allocation to each of the 2
reatment groups was in equal pro-
ortions. Both treatment groups
ere studied concurrently. Time
ero was defined as the time of
andomization, and patients were
onsidered enrolled in the study at
his time point. The same ran-
omly assigned stent had to be
mplanted in all lesions in patients
ho required stenting in multiple
esions, and the use of1 stent per
esion was also allowed. Patients were assigned to receive either
he sirolimus-eluting Cypher (Cordis) stent or paclitaxel-
luting Taxus stent (Boston Scientific).
An oral loading dose of 600 mg clopidogrel was admin-
stered to all patients before the intervention, regardless of
hether the patient was receiving clopidogrel before admis-
ion. During the procedure, patients were given intravenous
spirin, heparin, or bivalirudin; glycoprotein IIb/IIIa inhib-
tor usage was at the discretion of the operators. Procedural
uccess was defined as residual stenosis 30% and Throm-
olysis In Myocardial Infarction flow grade 3 achieved in
he treated vessel using the assigned stent. After the
ntervention, all patients, irrespective of treatment alloca-
ion, were prescribed 200 mg/day aspirin indefinitely, clo-
idogrel 150 mg for the first 3 days (or until discharge)
ollowed by 75 mg/day for at least 6 months, and other
ardiac medications according to the judgment of the
atient’s physician (e.g., beta-blockers, angiotensin-
onverting enzyme inhibitors, statins). After enrollment,
atients remained in the hospital for at least 48 h. Blood
amples were drawn every 8 h for the first 24 h after
andomization and daily afterward for the determination of
ardiac markers (creatine kinase, creatine kinase-myocardial
and, troponin T). Daily recording of the electrocardiogram
as also performed until discharge. All patients were eval-
ated at 1 and 12 months by phone or office visit. Repeat
oronary angiography was scheduled for all patients at 6 to
months.
ata management, end points, and definitions. Relevant
ata were collected and entered into a computer database by
pecialized personnel of the clinical data management
enter. All events were adjudicated and classified by an
vent adjudication committee blinded to the treatment
roups. Baseline, post-procedural, and follow-up coronary
ngiograms were digitally recorded and assessed off line in
he quantitative angiography (QCA) core laboratory
ISARESEARCH Center, Munich, Germany) with an
utomated edge-detection system (CMS version 7.1, Medis
Abbreviations
and Acronyms
DES  drug-eluting stent(s)
ISAR  individualizable
stent to abrogate
restenosis
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
QCA  quantitative
angiography
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularizationedical Imaging Systems, Ridgefield, Connecticut) by 2
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Treatment of SES Restenosis June 15, 2010:2710–6ndependent experienced operators unaware of the treat-
ent allocation. Measurements were performed on cinean-
iograms recorded after the intracoronary administration of
itroglycerine. Baseline QCA measurements were per-
ormed using the single worst view projection for the index
esion; the same view projection was used for the measure-
ents after stent implantation. In the follow-up angiogram,
he QCA measurements were performed using the single
orst view projection at that time point. The contrast-filled
ontapered catheter tip was used for calibration. Quantita-
ive analysis was performed on both the “in-stent” and
in-segment” area (including the stented segment, as well as
oth 5-mm margins proximal and distal to the stent).
estenosis morphology was adjudicated according to criteria
odified from Mehran et al. (11) Restenosis was defined as
iameter stenosis 50% in the in-segment area (including
tent area as well as 5-mm margins proximal and distal to
he stent). At baseline angiogram of the index lesion, the
tent was defined as the previously implanted SES. At
ollow-up angiogram of the recurrent restenotic lesion, the
tent was defined as the new implanted stent in the setting
f the present study (SES or PES).
The primary end point of the study was in-stent late
umen loss at follow-up angiography (defined as the differ-
nce between the minimal luminal diameter at the end of
he procedure and the minimal luminal diameter at
ollow-up angiography). Secondary end points were in-
egment binary angiographic restenosis, defined as diameter
tenosis 50% in the in-segment area (including the stent
rea as well as 5-mm margins proximal and distal to the
tent) at follow-up angiography; the need for target lesion
evascularization (TLR), defined as any revascularization
rocedure involving the target lesion due to luminal renar-
owing in the presence of symptoms or objective signs of
schemia at 1-year follow-up; the combined incidence of
eath or myocardial infarction; and the incidence of definite
tent thrombosis. A detailed definition of myocardial infarc-
ion has been previously described (12). Stent thrombosis
as classified according to Academic Research Consortium
riteria (13).
tatistical analysis. The objective of the study was to assess
he superiority of PES compared to SES for prevention of
ecurrent restenosis in patients who had undergone a prior
ES implantation. The null hypothesis regarding the pri-
ary end point was that there was no difference between the
ES and the PES. Sample size calculation was based on the
ethod for 2 independent means using the following
ssumptions: in-stent late luminal of 0.60 mm after repeated
ES implantation, in-stent late lumen loss of 0.40 mm after
ES implantation, a common standard deviation of 0.60
m, 2-sided alpha-level of 0.05, and power of 90%.
ccordingly, we estimated that 190 patients with angio-
raphic follow-up data per group were needed. To account
or possible losses to follow-up, a total of 450 patients was
nrolled. The analysis of primary and secondary end points
as planned to be performed on an intention-to-treat basis.
Dre-specified subsets of interest were old and young pa-
ients, men and women, diabetic and nondiabetic patients,
nd small and large vessels. Continuous data are presented
s mean (SD) or median (25th to 75th percentiles). Cate-
orical data are presented as counts or proportions (%).
ifferences between groups were checked for significance
sing Student t test for continuous data and chi-square test
or Fisher’s exact test where the expected cell value was 5)
or categorical variables. Survival was assessed using the
ethods of Kaplan-Meier and compared using the log-rank
est. Statistical software S-PLUS version 4.5 (S-PLUS,
nsightful Corp., Seattle, Washington) was used for analy-
is. Sample size calculation was performed using nQuery
dvisor (Statistical Solutions, Cork, Ireland).
esults
atient and lesion characteristics. A total of 450 patients
as enrolled in the ISAR-DESIRE 2 study and randomly
ssigned to receive either SES (n  225) or PES (n  225).
hey represent 90.2% of the 499 eligible patients treated for
estenosis. Of the 49 patients not enrolled in the study, 9
atients presented with acute myocardial infarction, 30 with
n-stent restenosis of the left main area, and 11 patients
efused study participation. Baseline characteristics of the
tudy patients are shown in Table 1, and they were well
atched between the 2 treatment groups. Diabetes mellitus
as present in 162 (36.0%) patients. Eighty-three (18.4%)
atients presented with acute coronary syndrome.
Angiographic and procedural characteristics are displayed
n Table 2. There were no significant differences between
he 2 treatment arms. In all, 243 lesions were treated in the
ES arm versus 240 in the PES arm (p  0.61).
estenosis stent type and morphology. In the SES group,
4 (38.7%) patients had received a Cypher SES at the time
f the initial procedure, with 149 (61.3%) receiving an
SAR SES. Of patients allocated to PES treatment, 92
aseline Patient CharacteristicsTable 1 Baseline Patient Characteristics
SES
(n  225)
PES
(n  225) p Value
Age, yrs 66.4 10.9 67.1 10.4 0.48
Female 47 (20.8) 58 (25.7) 0.22
Diabetes mellitus 86 (38.2) 76 (33.8) 0.32
Insulin-dependent 32 (14.2) 31 (13.8) 0.89
Hypertension 163 (72.4) 163 (72.4) 0.99
Hyperlipidemia 868 (66.8) 846 (64.9) 0.30
Current smoker 26 (11.6) 28 (12.4) 0.77
Prior myocardial infarction 102 (45.3) 100 (44.4) 0.85
Prior bypass surgery 38 (16.9) 43 (19.1) 0.54
Multivessel disease 197 (87.6) 195 (86.7) 0.77
Clinical presentation 0.40
Acute coronary syndrome 45 (20.0) 38 (16.9)
Stable angina 180 (80.0) 187 (83.1)
Ejection fraction, %* 52.5 11.9 54.0 10.6 0.21ata shown as mean  SD or n (%). *Data available for 88.0% of study sample (n  396).
PES  paclitaxel-eluting stent(s); SES  sirolimus-eluting stent(s).
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June 15, 2010:2710–6 Treatment of SES Restenosis38.3%) had received a Cypher stent, with 148 (61.7%)
reated with an ISAR SES (p  0.94). Overall, there were
o significant differences between the groups with regard to
estenosis morphology at presentation. The majority pre-
ented with a focal pattern of restenosis (SES n  158
65.0%] vs. PES n  146 [60.8%]; p  0.34) (details in
able 2). Procedural success was achieved in 242 (99.6%)
esions with SES versus 249 (100.0%) with PES (p 0.32).
ngiographic outcomes and recurrent restenosis morphology.
ngiographic follow-up data were available for 190 (84.8%)
atients and 191 (84.9%) patients treated with SES and
ES, respectively (p  0.98). Median time to surveillance
ngiography was 195 days (168 to 208 days) and 198 days
164 to 217 days), respectively (p  0.22). Angiographic
esults and the patterns of recurrent restenosis are displayed
n Table 3.
In terms of the primary angiographic end point, there was
o significant difference between the 2 groups. Mean late
oss was 0.40  0.65 mm in the SES group against 0.38 
.58 mm in the PES group (p  0.85) (Fig. 1). Similarly,
here were no significant differences between the groups in
ngiographic and Procedural CharacteristicsTable 2 Angiographic and Procedural Characteristics
SES
(n  243)
PES
(n  240) p Value
Initial SES 0.94
Cypher 94 (38.7) 92 (38.3)
ISAR stent 149 (61.3) 148 (61.7)
Target vessel 0.79
Left anterior descending artery 87 (35.8) 93 (38.8)
Left circumflex artery 68 (28.0) 65 (27.0)
Right coronary artery 88 (36.2) 82 (34.2)
Restenosis morphology 0.57
Type I (focal)
Focal marginal 51 (21.0) 45 (18.8)
Focal body 91 (37.5) 83 (34.6)
Multifocal 16 (6.6) 18 (7.5)
Type II (diffuse) 72 (29.6) 86 (35.8)
Type III (proliferative) 1 (0.4) 0 (0.0)
Type IV (occlusive) 12 (4.9) 8 (3.3)
Bifurcation 36 (14.8) 39 (16.2) 0.66
Ostial 39 (16.1) 41 (17.1) 0.76
Lesion length, mm 12.7 8.3 12.5 7.7 0.72
Vessel size, mm 2.78 0.47 2.75 0.48 0.50
Stenosis, pre-procedure, % 63.4 18.3 65.6 16.0 0.15
Minimal lumen diameter,
pre-procedure, mm
1.02 0.55 0.95 0.48 0.10
Balloon diameter, mm 3.07 0.48 3.08 0.50 0.76
Balloon pressure, maximum, atm 15.5 3.5 15.4 3.0 0.84
Minimal lumen diameter,
post-procedure, in-stent, mm
2.54 0.44 2.53 0.44 0.81
Minimal lumen diameter,
post-procedure, in-segment, mm
2.20 0.54 2.18 0.53 0.61
Stenosis, post-procedure, in-stent, % 11.8 7.3 11.3 7.1 0.49
Stenosis, post-procedure, in-segment, % 24.0 11.4 24.1 11.8 0.97
Procedural success 242 (99.6) 249 (100.0) 0.32ata shown as n (%) or mean  SD.
ISAR  individualizable stent to abrogate restenosis; other abbreviations as in Table 1.erms of binary restenosis (SES n  39 [19.0%] lesions
ersus PES n  42 [20.6%] lesions; p  0.69) (Fig. 2).
Regarding the analysis of the primary end point in
re-specified subgroups, lack of difference between the 2
tent types was observed in all pre-specified subgroups
efined by age, sex, diabetes, and vessel size (p value for
nteraction 0.15 in all cases). Neither were there any
ifferences between the 2 groups when patients were ana-
yzed according to the stent type implanted at the initial
ntervention (p value for interaction  0.49). Among
atients originally treated with a Cypher SES, mean late
oss with a second SES was 0.40  0.61 mm versus 0.43 
.64 mm with PES (p  0.73). Among patients initially
reated with a polymer-free SES, late loss with Cypher SES
ngiographic Outcomes at 6 to 8 MonthsTable 3 Angiographic Outcomes at 6 to 8 Months
SES
(n  205)
PES
(n  204) p Value
Minimal luminal diameter,
in-stent, mm
2.14 0.78 2.16 0.72 0.78
Minimal luminal diameter,
in-segment, mm
1.93 0.73 1.94 0.67 0.98
Stenosis, in-stent, % 26.6 23.6 25.4 21.5 0.53
Stenosis, in-segment, % 34.0 21.1 33.3 18.7 0.73
Late loss, in-stent, mm 0.40 0.65 0.38 0.59 0.85
Late loss, in-segment, mm 0.26 0.61 0.25 0.58 0.86
Recurrent binary restenosis 39 (19.0) 42 (20.6) 0.69
Restenosis morphology 0.42
Type I (focal)
Focal marginal 9 (23.0) 14 (33.2)
Focal body 18 (46.1) 11 (26.3)
Multifocal 4 (10.3) 6 (14.3)
Type II (diffuse) 4 (10.3) 7 (16.7)
Type III (proliferative) 0 (0.0) 0 (0.0)
Type IV (occlusive) 4 (10.3) 4 (9.5)
ata shown as mean  SD or n (%).
Abbreviations as in Table 1.
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Figure 1 Cumulative Frequency Distribution Curves
for In-Stent Late Luminal Loss
The gold line indicates paclitaxel-eluting stents (PES);
the blue line indicates sirolimus-eluting stents (SES).
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Treatment of SES Restenosis June 15, 2010:2710–6as 0.40  0.68 mm versus 0.34  0.56 mm with PES
p  0.49).
linical outcomes. At 12 months, there were no significant
ifferences between the 2 groups in terms of clinical results
Table 4). TLR was required in 35 (16.6%) patients treated
ith SES as compared with 30 (14.6%) patients treated with
ES (p  0.52) (Fig. 2). Two (0.8%) patients treated with
ES were in need of bypass surgery as compared with 1 (0.4%)
atient treated with PES (p  0.56). Target vessel revascular-
zation was performed in 50 (23.7%) patients treated with
ypher versus 47 (22.8%) patients treated with Taxus
p  0.82).
Regarding safety end points, there were no differences in
he composite of death or myocardial infarction (SES 13
6.1%] vs. PES 12 [5.8%]; p  0.86) or the rate of definite
tent thrombosis (SES 1 [0.4%] vs. PES 1 [0.4%]; p 
.67). Both stent thrombosis events occurred after 30 days.
In terms of overall major adverse cardiovascular events,
here was no difference in the composite of death, myocar-
ial infarction, or target lesion revascularization (SES n 
4 [20.4%] vs. PES n  41 [19.6%]; p  0.71) (Fig. 3).
In relation to antiplatelet therapy, 61.2% of patients
reated with SES and 64.9% of patients treated with PES
ere still receiving dual antiplatelet therapy 1 year after
ntervention (p  0.49). For patients who stopped dual
16.6 14.6
0
10
20
30
Clinical Restenosis
19.0
20.6
0
10
20
30
Angiographic Restenosis
%
p=0.69 p=0.52
Figure 2 Angiographic Restenosis at 6 to 8 Months
and Clinical Restenosis at 1 Year
The blue bars indicate SES; the gold bars indicate PES. Clinical restenosis
refers to target lesion revascularization. Abbreviations as in Figure 1.
linical Results at 1 YearTable 4 Clinical Results at 1 Year
SES
(n  225)
PES
(n  225) p Value
Death 7 (3.4) 9 (4.5) 0.60
Myocardial infarction 6 (2.7) 4 (1.8) 0.53
Death or myocardial infarction 13 (6.1) 12 (5.8) 0.86
Definite stent thrombosis 1 (0.4) 1 (0.4) 0.67
Death, myocardial infarction, or
stent thrombosis
13 (6.1) 13 (6.3) 0.98
Death, myocardial infarction, or
target lesion revascularization
44 (20.4) 41 (19.6) 0.71t
ata shown as n (% are Kaplan-Meier estimates); p value from log-rank test.
Abbreviations as in Table 1.ntiplatelet therapy, median time to clopidogrel discontin-
ation was 223 days (range 188 to 340 days) for patients
reated with SES and 239 days (range 200 to 344 days) for
atients treated with PES (p  0.68).
iscussion
he principal findings of the ISAR-DESIRE 2 study are
hat in cases of DES restenosis occurring within a SES:
) the implantation of a second DES is feasible and safe;
) a strategy of either repeat SES implantation or switch to
PES is associated with comparable anti-restenotic efficacy;
nd 3) the neointimal inhibition observed with repeat SES
mplantation is somewhat lower than expected, indicative
erhaps of the existence of some degree of drug hypore-
ponsiveness at an individual patient level.
The widespread adoption of DES therapy coupled with
n overall increase in the number of PCI procedures has
enerated significant absolute numbers of patients present-
ng with DES restenosis (2). Clinically, the treatment of
hese DES restenotic lesions seems to be associated with
lightly higher rates of recurrent restenosis than that ob-
erved after treatment of bare-metal stent restenosis. For
xample, the use of DES to treat bare-metal stent restenosis
as been associated with repeat TLR rates at or just below
0% in most studies (6–8,14). Conversely, the use of DES
o treat DES restenosis carries with it a TLR rate in the
ange of 10% to 20% (3–5,14–17). Pathological differences
n plaque morphology as compared with bare-metal stent
estenosis may also exist—for example, obstructive DES
estenotic plaques may be characterized by a proliferative
xpansion of cell-depleted amorphous extracellular matrix
nd a possible excess of in-stent atherosclerosis (18).
Catheter-based treatment of bare-metal stent in-stent
estenosis was most effectively accomplished by DES im-
lantation. In the setting of randomized controlled trials,
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Figure 3 Composite of Death, MI, or TLR
The gold line indicates PES; the blue line indicates SES. MI  myocardial
infarction; TLR  target lesion revascularization; other abbreviations as in Figure 1.his proved superior to both plain balloon angioplasty (6,9)
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June 15, 2010:2710–6 Treatment of SES Restenosisnd vascular brachytherapy (7,8). Nevertheless, for patients
ith DES restenosis, the optimal management approach
emains to be defined.
As the predominant pattern of restenosis within DES is
ocal—exemplified by approximately two-thirds of cases in
he current study—catheter-based intervention would ap-
ear to be the most attractive initial treatment option for
his disease. In this respect, the optimal balance between
aximal acute gain and minimal late loss is likely to remain
ith repeat DES implantation. The current study adds to
arlier registry experience on this strategy and indicates that
epeat DES implantation is a feasible and safe approach.
lthough concern has always existed regarding the advis-
bility of the implantation of multiple stent layers in the
ame arterial segment, no evidence of any adverse safety
ignal was observed out to 12 months, with a rate of definite
tent thrombosis of 0.4% for the study population as a
hole. In terms of clinical efficacy, the overall rate of TLR
t 12 months (approximately 15%) is remarkably consistent
ith that of earlier nonrandomized studies (3–5,15–17) and
as not different between the SES and PES treatment
roups. This latter observation was mirrored in the com-
arative magnitude of late loss (SES 0.40  0.65 mm vs.
ES 0.38 0.59 mm) between the 2 stent platforms and in
eeping with the null hypothesis of the study (H0 not
ejected, p  0.85).
These findings have at least 2 implications. First of all,
rom a practical point of view, when faced with a patient
ith SES restenosis requiring repeat intervention, the cli-
ician may chose between a strategy of either repeat SES
mplantation or switch to PES therapy, with an expectation
f similar clinical outcome from either approach. Second,
rom a theoretical standpoint, the findings are unusual in
ertain respects as the Cypher stent has tended to outperform
he Taxus stent in higher-risk patient subsets (6,19–21). The
quivalent efficacy of both stents is most likely related to a
elative underperformance of the Cypher SES, which might be
elated to sirolimus hyporesponsiveness at an individual patient
evel in the population under study. As evidence of this, the
ngiographic anti-restenotic efficacy of the SES is somewhat
oorer than would be expected from the results of previous
tudies that enrolled enriched patient populations. In the
SAR-DESIRE study, the Cypher SES showed a mean
n-stent late luminal loss of 0.21  0.59 mm in patients with
are-metal stent restenosis (6). In diabetic patients studied in
he ISAR-DIABETES trial, the same stent was associated
ith a late loss of 0.19  0.44 mm (19); and in the setting of
mall vessels (20), the value was 0.23  0.55 mm. Notwith-
tanding the difficulties encountered in historical comparison,
he mean late loss observed with the SES in the current
tudy—0.40  0.65 mm—is an outlier and supports the
xistence of relative resistance to sirolimus in patients present-
ng with SES restenosis.
Resistance to sirolimus is well described in the oncology
iterature. The drug exerts its antiproliferative effects by
omplexing with FKBP12 and inhibiting the function of the tammalian target of rapamycin (mTOR)—an evolutionar-
ly conserved protein kinase with a key role in cell growth,
roliferation, and survival. Resistance may be conferred by
utations either in the FKBP12 (preventing initial com-
lexing) or in the FRB domain of mTOR (which inhibits
inding of the drug-protein complex to the mTOR recep-
or) (22). Furthermore, downstream resistance linked to
efective regulation of 3 key mTOR signaling pathways—
E-BP1, S6K1, and p27kip—has also been described (22).
he existence of a similar hyporesponsiveness phenomenon
fter local drug delivery to the coronary vessel wall would
ot be entirely unexpected.
Some important issues in the management of DES
estenosis remain to be addressed. First, whether these
esults are applicable to the treatment of restenosis occurring
ithin newer DES is open to discussion. This question
ould be definitively answered by specifically designed ran-
omized trials. Second, if ability to identify drug resistance
n particular patients develops, this might conceivably be
sed to guide therapy. Third, although results with drug-
luting balloon therapy show promise in cases of bare-metal
tent restenosis (23), the place of this therapy in cases of
ES restenosis awaits definition and will be the subject of
uture investigation (the ISAR-DESIRE-3 study; clinical-
rials.gov identifier NCT00987324).
tudy limitations. As with any study utilizing an angio-
raphic end point, conclusions are based on incomplete data
bservations. In this respect, it is notable that the overall
ngiographic follow-up rate (almost 85%) was above the
hreshold at which such end points are considered to be
obust surrogates of device efficacy (24). In addition, the
ptimal time point for adjudication of DES anti-restenotic
fficacy remains to be defined, as evidence suggests that
ngoing delayed late luminal loss beyond the usual 6- to
-month time window is a feature of first-generation DES
herapy (25). Furthermore, the influence of angiographic
ollow-up on the absolute rate of TLR should be consid-
red. This may increase the incidence of TLR in a manner
hat may not reflect routine clinical practice, although the
elative magnitude of an observed treatment effect may be
xpected to be real (26). Additionally, 60% of the patients
ere treated because of restenosis in an ISAR-SES, a stent
hat is not widely available. Although the late loss for Taxus
as numerically slightly lower among patients in whom the
nitial stent implanted was an ISAR-SES, as distinct
rom a Cypher SES, there was no statistically significant
nteraction between treatment assignment and type of
ES implanted at the initial intervention. Finally, regard-
ng safety outcomes, this study was not powered to detect
difference in rarely occurring clinical events such as
tent thrombosis.
onclusions
he findings of the ISAR-DESIRE 2 study demonstrate
hat, in cases of SES restenosis, both SES and PES are
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Treatment of SES Restenosis June 15, 2010:2710–6ssociated with a comparable degree of anti-restenotic
fficacy and clinical safety. The somewhat higher than
xpected late loss with the SES in the current study suggests
hat drug resistance at an individual patient level plays a
ontributory role in SES restenosis.
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